Troubles de l’éjaculation et sclérose en plaques : étude prospective de 44 patients

Classification and management of sexual dysfunctions in multiple sclerosis patients: A review of current literature

“…Results showed the presence of dysejaculation in 64% of MS patients, with a decrease in the strength of ejaculation, in the volume of the ejaculation, and in the delay of ejaculation. 38…”

“…Results showed the presence of dysejaculation in 64% of MS patients, with a decrease in the strength of ejaculation, in the volume of the ejaculation, and in the delay of ejaculation. 38 The first-line therapy for ED in patients affected by neurological disorders is considered treatment with phosphodiesterase-5 inhibitors (PDE5i). 39 Recently, three studies on the role of PDE5i in MS patients have been published; two of these were randomized double-blind trial of sildenafil versus placebo, 40,41 the other was a case series study of tadalafil.…”

Managing Urological Disorders in Multiple Sclerosis Patients: A Review of Available and Emerging Therapies

“…In terms of their overall satisfaction with sexual life, 11 patients (28.2%) considered themselves to be severely dissatisfied, 10 (25.6%) reported being moderately dissatisfied, and only 6 patients (15.4%) were satisfied [45]. A recent prospective, monocentric, noninterventional study investigated the prevalence of ejaculation disorders in MS patients, and showed that dysejaculation was present in 64% of MS patients, including a decrease in the volume of the ejaculation, the strength of ejaculation, and delay in ejaculation [46].…”